Hem/Onc News.
Authors: Schuyler D PMID: 27930633 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Ode to Bob.
Authors: Cheson BD PMID: 27930634 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Optimal treatment of unresectable stage III non-small cell lung cancer.
Authors: Bradley JD PMID: 27930635 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

What hematologists need to know about acute hepatic porphyria.
Authors: Balwani M PMID: 27930636 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of drug transporters as therapeutic targets.
Authors: Giacomini KM PMID: 27930637 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Guideline recommendations for the prophylaxis of invasive aspergillosis in AML.
Authors: Wang ES PMID: 27930638 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New treatments for bladder cancer.
Authors: Hahn NM PMID: 27930639 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patients.
Authors: Short NJ, Jabbour E PMID: 27930640 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is not necessary, at least in induction.
Authors: Chiaretti S PMID: 27930641 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?
Authors: Patel DN, Figlin RA, Kim HL Abstract Clinical parameters can be used to identify patients at greatest risk for recurrence following nephrectomy for clinically localized renal cell carcinoma (RCC). Molecular tools are being developed to improve risk stratification. An increasing list of available treatments for metastatic RCC continues to provide hope that an effective adjuvant therapy will be identified for patients with high-risk, clinically localized disease. In a phase 3 adjuvant therapy trial (S-TRAC), sunitinib increased median disease-free survival in patients with clear cell RCC who were at very hig...
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 27930643 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
Authors: McArthur HL, Page DB Abstract Immunotherapy encompasses both vaccines that direct immune responses to tumor-associated antigens, and checkpoint blocking antibodies that inhibit immune system suppression by targeting key pathways mediated by cytotoxic T-lymphocyte-associated antigen 4, programmed death 1 (PD-1), and programmed death ligand 1 (PD-L1). Both of these approaches currently are being explored as potential strategies for the treatment of breast cancer. Recent studies suggest that immunotherapy is poised to change the therapeutic landscape for some breast cancers. Specifically, overall response rat...
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

When to initiate treatment in myelofibrosis.
Authors: Harrison C PMID: 27930645 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: From 2003 to today.
Authors: Cheson BD PMID: 27673281 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The importance of dose optimization prior to initiation of a registration trial.
Authors: Rahman NA PMID: 27673282 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Consolidation therapy after autologous stem cell transplant in relapsed/refractory Hodgkin lymphoma.
Authors: Moskowitz CH PMID: 27673283 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging treatment options for carcinoid syndrome.
Authors: Kulke MH PMID: 27673284 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Special concerns for survivors of prostate cancer.
Authors: Peterson AC PMID: 27673285 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Zika and the safety of the US blood supply.
Authors: Busch MP PMID: 27673286 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of brain metastases in breast cancer.
Authors: Anders CK PMID: 27673287 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Authors: Chery LJ, Karam JA, Wood CG Abstract The incidence of renal cell carcinoma is increasing, with up to one-third of patients presenting with metastatic disease. Combination therapy is used to prolong survival in patients with metastatic renal cell carcinoma, which carries a poor prognosis. Although two pivotal phase 3 trials have demonstrated the efficacy of immunotherapy after cytoreductive nephrectomy for metastatic disease, for now, targeted therapy has replaced immunotherapy as the preferred systemic treatment in these patients. Two ongoing phase 3 trials are evaluating the role of cytoreductive nephrect...
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
This article reviews the development of PARP inhibitors other than olaparib, and discusses the evidence for PARP inhibitors beyond BRCA1/2-mutant ovarian cancer. PMID: 27673289 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Authors: Voorhees PM, Usmani SZ Abstract The advent of the immunomodulatory drugs thalido-mide, lenalidomide, and pomalidomide; the proteasome inhib-itors bortezomib, carfilzomib, and ixazomib; the histone deacet-ylase inhibitor panobinostat; and the monoclonal antibodies elotuzumab and daratumumab has led to dramatic improvements in outcomes for patients with multiple myeloma. Along with progress in nontransplant therapy have come questions regarding the continued role of high-dose melphalan (HDM) supported by autologous stem cell transplant (ASCT) in the treatment of multiple myeloma. Emerging evidence from phase...
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Correction: Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Authors: Abstract An article in the July 2016 issue, "Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma" by Gaurav Varma, MSPH, Tyler P. Johnson, MD, and Ranjana H. Advani, MD, described ONO/GS-4059 as a "reversible" inhibitor of BTK when it is in fact an "irreversible" inhibitor. We have made the correction to pages 546 and 552 of the online version at www.hematologyandoncology.net. Many thanks to an astute reader for pointing out the error. This corrects the article pmid:27379948. PMID: 27673291 [PubMed - as supplied by publisher] (Source: Clinical...
Source: Clinical Advances in Hematology and Oncology - September 29, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter from the editor: the campaign button.
Authors: Cheson BD PMID: 27487098 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
Authors: Andtbacka RH PMID: 27487099 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Are we ready for precision medicine in acute myeloid leukemia?
Authors: Roboz GJ PMID: 27487100 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Authors: Geschwind JF, Chapiro J PMID: 27487101 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in kidney cancer from the 2016 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 27487102 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent advances in the management of myelofibrosis.
Authors: Mesa RA PMID: 27487103 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Improving clinical trial design through quantitative pharmacology.
Authors: Maitland ML PMID: 27487104 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Moving beyond monotherapy in the immunotherapeutic arena: prospects for combination therapies in lung cancer.
Authors: Antonia SJ PMID: 27487105 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
This article reviews the development of olaparib for ovarian cancer and discusses the current evidence for its use, ongoing studies, future research directions, and the challenges ahead. PMID: 27487106 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer.
Authors: Weinberg BA, Marshall JL, Salem ME Abstract Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States. Approximately 20% of patients have metastatic disease at diagnosis, and a vast number of these patients die within 5 years. The advent of modern chemotherapeutics has improved median overall survival for these patients; nonetheless, we must keep striving for better outcomes. Trifluridine/tipiracil (TAS-102) and regorafenib are agents newly approved by the US Food and Drug Administration that show promise in the treatment of metastatic colorectal cancer. These drugs h...
Source: Clinical Advances in Hematology and Oncology - August 5, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator ’s Choice (LUMIERE trial; NCT01482962).
First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator’s Choice (LUMIERE trial; NCT01482962). Clin Adv Hematol Oncol. 2016 Feb;14(2 Suppl 1):12-3 Authors: PMID: 27466629 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current understanding of resistance to abiraterone   and enzalutamide in advanced prostate cancer.
Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer. Clin Adv Hematol Oncol. 2016 May;14(5):316-9 Authors: Antonarakis ES PMID: 27379691 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 22, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: The pedant and the scoundrel.
Authors: Cheson BD PMID: 27379689 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

FDA regulation of laboratory-developed tests.
Authors: Miller VA PMID: 27379690 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer. Clin Adv Hematol Oncol. 2016 May;14(5):316-9 Authors: Antonarakis ES PMID: 27379691 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Preventive strategies for invasive Aspergillus in acute myelogenous leukemia.
Authors: Schiller G PMID: 27379692 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Authors: Woyach JA PMID: 27379693 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
Authors: Wendtner CM PMID: 27379694 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 27379695 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

HSP90 inhibitors in lung cancer: promise still unfulfilled.
Authors: Chatterjee S, Bhattacharya S, Socinski MA, Burns TF Abstract Despite recent advances in the treatment of lung cancer, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the United States and worldwide, with a 5-year survival rate of less than 17%. Analysis of the molecular drivers of NSCLC led to the recognition that NSCLC is a collection of distinct, molecularly driven neoplasms. Several subsets of NSCLC with clinical relevance to targeted therapies are defined based on alterations in EGFR, ALK, and other key oncogenic drivers. However, for many oncogenic drivers-such...
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: When Breath Becomes Air.
Authors: Cheson BD PMID: 27379805 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Checkpoint inhibitors in breast cancer: hype or promise?
Authors: McArthur HL PMID: 27379806 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Personalized treatment for patients with myelofibrosis.
Authors: Kadia TM PMID: 27379807 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Surveillance for hepatocellular carcinoma.
Authors: Frenette C PMID: 27379808 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 27379809 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
Authors: Atkins MB PMID: 27379810 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research